TAPA-pulsed dendritic cell vaccine + cyclophosphamide + sargramostim

A **combination immunotherapeutic regimen** composed of an autologous dendritic cell vaccine pulsed with tumor-associated peptide antigens (TAPA), combined with the chemotherapeutic cyclophosphamide and the cytokine sargramostim (recombinant human granulocyte-macrophage colony-stimulating factor, GM-CSF). The TAPA-pulsed dendritic cell vaccine is designed to elicit T cell-mediated immune responses specifically against tumor cells expressing the targeted peptide antigens. Cyclophosphamide is included for its immunomodulatory and cytotoxic effects, potentially decreasing regulatory T cell populations and enhancing vaccine-induced immune responses. Sargramostim is used to stimulate proliferation and differentiation of granulocyte and macrophage lineages, supporting immune recovery and enhancing dendritic cell activity. The combination has been investigated in clinical trials primarily for advanced or refractory solid and hematological malignancies, aiming to enhance anti-tumor responses through multiple immunologic and cytotoxic mechanisms[3][5].